ID

34430

Description

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification; ODM derived from: https://clinicaltrials.gov/show/NCT02468661

Lien

https://clinicaltrials.gov/show/NCT02468661

Mots-clés

  1. 17/01/2019 17/01/2019 -
  2. 20/04/2020 20/04/2020 -
  3. 25/04/2020 25/04/2020 -
Détendeur de droits

see on clinicaltrials.gov

Téléchargé le

17 janvier 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Non-Small Cell Lung Cancer NCT02468661

Eligibility Non-Small Cell Lung Cancer NCT02468661

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
locally advanced or metastatic nsclc
Description

ID.1

Type de données

boolean

egfr mutation (l858r and /or ex19del)
Description

ID.2

Type de données

boolean

cmet amplification by fish (gcn ≥ 6),
Description

ID.3

Type de données

boolean

acquired resistance to egfr tki (1st or 2nd génération)
Description

ID.4

Type de données

boolean

ecog performance status (ps) ≤ 1.
Description

ID.5

Type de données

boolean

Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior treatment with 3rd generation tki
Description

ID.6

Type de données

boolean

phaseii : prior treatment with any of the following agents:
Description

ID.7

Type de données

boolean

crizotinib, or any other cmet inhibitor or hgf-targeting inhibitor.
Description

ID.8

Type de données

boolean

concomitant egfr tki and platinum based chemotherapy as first line regimen.
Description

ID.9

Type de données

boolean

platinum-based chemotherapy as first line treatment
Description

ID.10

Type de données

boolean

Similar models

Eligibility Non-Small Cell Lung Cancer NCT02468661

Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
locally advanced or metastatic nsclc
boolean
ID.2
Item
egfr mutation (l858r and /or ex19del)
boolean
ID.3
Item
cmet amplification by fish (gcn ≥ 6),
boolean
ID.4
Item
acquired resistance to egfr tki (1st or 2nd génération)
boolean
ID.5
Item
ecog performance status (ps) ≤ 1.
boolean
Item Group
C0680251 (UMLS CUI)
ID.6
Item
prior treatment with 3rd generation tki
boolean
ID.7
Item
phaseii : prior treatment with any of the following agents:
boolean
ID.8
Item
crizotinib, or any other cmet inhibitor or hgf-targeting inhibitor.
boolean
ID.9
Item
concomitant egfr tki and platinum based chemotherapy as first line regimen.
boolean
ID.10
Item
platinum-based chemotherapy as first line treatment
boolean

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial